摘要
视网膜静脉阻塞是常见致盲眼病,黄斑囊样水肿、视网膜新生血管和新生血管性青光眼是其预后差的主要原因,缺血、缺氧是形成视网膜新生血管的主要原因。血管内皮生长因子和色素上皮衍生因子、内皮抑素在新生血管的形成中起重要作用。Bevacizumab(avastin)是重组人血管内皮生长因子的单克隆抗体,在抑制新生血管、减轻黄斑水肿有显著效果,有望应用于治疗视网膜静脉阻塞的常见并发症之一——视网膜新生血管。
Retinal vein occlusion（RVO） is a common blind causing ophthalmopathy, and cystoid macular edema（CME）, retinal neovascu- larization（RNV） and neovascular glaucoma are the main reasons for its poor prognosis. Ischemia and lack of oxygen are the main causes of retinal neovascularization formation. Vascular endothelial growth factor（VEGF） and Pigment epithelium - derived factor（PEDF）, Endostatin（ES） play an important role in the formation of new blood vessels. Bevaciztunab（avastin）is a recombinant human vascular endothelial growth factor monoclonal antibody, playing a significant effect in inhibiting retinal neovascularization and reducing macular edema, and it is expected in the treatment of retinal neovascularization, which is one of the common complications of retinal vein occlusion.
出处
《中国中医眼科杂志》
2008年第2期116-119,共4页
China Journal of Chinese Ophthalmology
